Biogen completed construction in late spring of 2020 on a leading-edge biologics manufacturing center in Luterbach, Switzerland. Representing an investment of $1.5 billion, the modular and flexible facility leverages Biogen’s latest strategies for fed-batch cell culture technologies and protein purification processes. Offering two cell manufacturing lines, the 260,000-sf complex features two production buildings, each housing four 15,000-liter bioreactors. The campus also provides laboratories, offices, maintenance buildings, and a warehouse. Commissioning will continue through 2020 with commercial-scale production commencing in mid-2021.
Jacobs was the engineer, construction manager, and procurement agent for the project, which was built by Marti Solothurn. Siemens' Desigo CC building management platform will enable the complex to operate with optimal efficiency, safety, resilience, and comfort.